IPP Bureau

Kwality Pharma received approval for Leuprorelin Acetate for injectable suspension from Greece
Kwality Pharma received approval for Leuprorelin Acetate for injectable suspension from Greece

By IPP Bureau - November 07, 2024

KIMS to acquire 3,000 beds in next 5 years in Kerala
KIMS to acquire 3,000 beds in next 5 years in Kerala

By IPP Bureau - November 07, 2024

The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode

Mitsui Chemicals begins sale of i-TFC luminous II dental material range
Mitsui Chemicals begins sale of i-TFC luminous II dental material range

By IPP Bureau - November 07, 2024

The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range

Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro

By IPP Bureau - November 07, 2024

The company uses iPS cells to develop treatments for diseases relating to the kidney

Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr
Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr

By IPP Bureau - November 07, 2024

Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024

Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr
Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr

By IPP Bureau - November 07, 2024

Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024

Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting
Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

By IPP Bureau - November 07, 2024

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

By IPP Bureau - November 07, 2024

US Generics grew 5% to Rs. 467 Crores for the quarter

Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr

By IPP Bureau - November 07, 2024

Revenue growth was fueled by higher volumes and contributions from both existing and new centres

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

By IPP Bureau - November 07, 2024

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

By IPP Bureau - November 06, 2024

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

By IPP Bureau - November 06, 2024

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities

Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr
Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr

By IPP Bureau - November 06, 2024

Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024

Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion

By IPP Bureau - November 06, 2024

Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

By IPP Bureau - November 06, 2024

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24

Latest Stories

Interviews

Packaging